Companies appreciate our depth of experience in areas including pharmaceuticals, biotechnology, and diagnostic and medical devices. Since 2010, we have completed approximately 575 capital markets transactions in healthcare, totaling over $470 billion. Over the same period, we advised on more than 200 M&A transactions, with a cumulative deal value of approximately $1.2 trillion and a market share of approximately 25%, according to data from Refinitiv.
Healthcare and life sciences clients trust in our understanding of the complex issues they face in acquisitions, divestitures, joint ventures, partnerships, strategic alliances, licensing arrangements, collaborations, distribution agreements, internal investigations and litigation.
Many transactions and other matters have an intellectual property component. Clients appreciate that our team includes lawyers with strong biomedical backgrounds such as Ph.D.s and biomedical engineering degrees.
We work with top multinationals and are a firm of choice for companies going public. Recent IPOs include American Well, BioNTech, CureVac, Freeline, GoodRx, Signify Health, Royalty Pharma and Vaccitech.
Our M&A clients include many of the largest developers of therapies, treatments and devices, including AstraZeneca, Bausch Health, Bristol Myers Squibb, Gilead, Novo Nordisk, Pfizer and Roche.
Numerous healthcare companies and credit arrangers have turned to us for advice on revolving and term loan facilities and on bridge loans facilities entered into in conjunction with business combinations.
We advise clients on transactions including complex licensing and collaboration arrangements, the disposal of research and development programs, and the acquisition of product rights.
Clients have sought our help on civil, regulatory and enforcement matters involving bribery, false advertising and fraud, product safety, securities litigation, off-label promotion and patent misuse.